Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
Quarterly results
Acq. announced
|
|
Panbela Therapeutics, Inc. (SNBP)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 11/14/2017 |
8-K
| Quarterly results |
| 08/10/2017 |
8-K
| Quarterly results |
| 05/11/2017 |
8-K
| Form 8-K - Current report |
| 11/10/2016 |
8-K
| Form 8-K - Current report |
| 08/11/2016 |
8-K
| Quarterly results|
Docs:
|
"Three Months Ended June 30, Percent Six Months Ended June 30, Percent 2016 2015 Change 2016 2015 Change Operating expenses: General and administrative $ 419 $ 585 % $ 900 $ 1,788 % Research and development 530 608 1,024 1,596 Operating loss Other income : Interest income 1 3 2 5 Interest expense 4.6 Other income 341.2 7 nm Total other income 98.3 Loss before income tax benefit Income tax benefit 90 38 136.8 206 95 116.8 Net loss $ $ $ $ Foreign currency translation adjustment gain 42 nm 153.8 Comprehensive loss $ $ % $ $ % Basic and diluted net loss per share $ $ % $ $ % Weighted average shares outstanding—basic and diluted 30,126,755 6,585,533 357.5 % 30,058,942 6,225,722 382.8.0 % Sun BioPharma, Inc. Consolidated Balance Sheets ASSETS Current assets: Cash and cash equivale..." |
|
|
|